Phosphorylation of α-synuclein Protein at Ser-129 Reduces Neuronal Dysfunction by Lowering Its Membrane Binding Property in Caenorhabditis Elegans
Overview
Affiliations
α-Synuclein is causative for autosomal dominant familial Parkinson disease and dementia with Lewy bodies, and the phosphorylation of α-synuclein at residue Ser-129 is a key posttranslational modification detected in Parkinson disease/dementia with Lewy bodies lesions. However, the role of Ser-129 phosphorylation on the pathogenesis of Parkinson disease/dementia with Lewy bodies remains unclear. Here we investigated the neurotoxicity of Ser-129-substituted α-synuclein in the transgenic Caenorhabditis elegans (Tg worm) model of synucleinopathy. Tg worms pan-neuronally overexpressing nonphosphorylatable (S129A) α-synuclein showed severe defects including motor dysfunction, growth retardation, and synaptic abnormalities. In contrast, Tg worms expressing phosphorylation mimic (S129D) α-synuclein exhibited nearly normal phenotypes. Biochemical fractionation revealed that the level of membrane-bound α-synuclein was significantly increased in S129A-α-synuclein Tg worms, whereas S129D- as well as A30P-α-synuclein displayed lower membrane binding properties. Furthermore, A30P/S129A double mutant α-synuclein did not cause neuronal dysfunction and displayed low membrane binding property. In human neuroblastoma SH-SY5Y cells, localization of S129A-α-synuclein to membranes was significantly increased. Finally, gene expression profiling of S129A-Tg worms revealed a dramatic up-regulation of Daf-16/FOXO pathway genes, which likely act against the dysfunction caused by S129A-α-synuclein. These results imply a role of Ser-129 phosphorylation of α-synuclein in the attenuation of α-synuclein-induced neuronal dysfunction and downstream stress response by lowering the membrane binding property.
Abe T, Kuwahara T, Suenaga S, Sakurai M, Takatori S, Iwatsubo T iScience. 2024; 27(2):108893.
PMID: 38313055 PMC: 10835446. DOI: 10.1016/j.isci.2024.108893.
Battis K, Xiang W, Winkler J Int J Mol Sci. 2023; 24(17).
PMID: 37686080 PMC: 10487772. DOI: 10.3390/ijms241713270.
Maor G, Dubreuil R, Feany M J Neurosci. 2023; 43(9):1614-1626.
PMID: 36653193 PMC: 10008058. DOI: 10.1523/JNEUROSCI.1922-22.2022.
Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson's Disease.
Raghunathan R, Turajane K, Wong L Int J Mol Sci. 2022; 23(16).
PMID: 36012563 PMC: 9409485. DOI: 10.3390/ijms23169299.
Dual Effects of Presynaptic Membrane Mimetics on -Synuclein Amyloid Aggregation.
Lin Y, Ito D, Yoo J, Lim M, Yu W, Kawata Y Front Cell Dev Biol. 2022; 10:707417.
PMID: 35747692 PMC: 9209734. DOI: 10.3389/fcell.2022.707417.